Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation metrics demonstrate a cyclical trajectory characterized by a sustained expansion phase from early 2022 through late 2024, followed by a pronounced contraction and a subsequent partial recovery toward the end of the analyzed period.
- Price to Earnings (P/E) Ratio
- The P/E ratio exhibited a general upward trend from 55.10 in March 2022, peaking at 87.82 in December 2024. This period of expansion suggests a significant increase in market premium relative to earnings. A sharp decline followed, reaching a period low of 39.40 in June 2026, before recovering to 50.18 by September 2026.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio mirrored the P/E trend, starting at 49.98 in March 2022 and reaching its maximum value of 89.92 in September 2024. The subsequent contraction was equally steep, bottoming out at 35.83 in June 2026 and closing the period at 45.19 in September 2026, indicating a realignment of the stock price relative to operating performance.
- Price to Sales (P/S) Ratio
- A notable expansion in revenue valuation is observed, with the P/S ratio rising from 15.34 in March 2022 to a peak of 24.42 in December 2024. This metric saw a significant correction starting in 2025, dropping to 11.21 in June 2026, which represents the lowest valuation relative to sales across the entire timeframe, before a slight increase to 12.82 in September 2026.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio followed the broader valuation trend, increasing from 7.48 in March 2022 to a peak of 12.41 in December 2024. A subsequent decline led to a low of 6.81 in June 2026, followed by a recovery to 9.28 by September 2026, reflecting volatility in the market's assessment of the company's net asset value.
Across all four metrics, the period ending December 2024 represents a valuation ceiling, while June 2026 marks a valuation floor. The synchronized movement of these ratios suggests that the shifts were driven primarily by changes in stock price rather than isolated fluctuations in earnings, sales, or book value.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 346,643,718 | 353,278,038 | 354,162,842 | 355,130,237 | 354,496,073 | 358,476,506 | 358,418,255 | 356,656,964 | 356,179,445 | 355,354,176 | 354,705,822 | 352,325,863 | 352,071,592 | 351,354,675 | 350,398,068 | 350,389,679 | 353,384,570 | 357,111,192 | 358,956,511 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. (in thousands) | 522,800) | 818,100) | 821,500) | 794,800) | 704,400) | 658,400) | 698,400) | 685,700) | 565,100) | 526,900) | 544,900) | 606,200) | 415,700) | 420,800) | 355,300) | 324,900) | 324,000) | 307,800) | 365,600) | ||||||
| Earnings per share (EPS)2 | 8.53 | 8.88 | 8.41 | 8.04 | 7.75 | 7.27 | 6.91 | 6.51 | 6.30 | 5.89 | 5.60 | 5.10 | 4.31 | 4.06 | 3.74 | 3.77 | 3.90 | 4.02 | 4.58 | ||||||
| Share price1, 3 | 428.12 | 350.06 | 483.62 | 478.88 | 527.03 | 501.95 | 487.93 | 571.88 | 521.15 | 455.01 | 366.34 | 378.22 | 266.91 | 323.56 | 297.41 | 245.27 | 218.49 | 211.85 | 252.34 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | 50.18 | 39.40 | 57.49 | 59.55 | 68.01 | 69.00 | 70.63 | 87.82 | 82.75 | 77.23 | 65.38 | 74.11 | 61.96 | 79.78 | 79.43 | 64.99 | 56.03 | 52.74 | 55.10 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| Abbott Laboratories | 42.56 | 34.22 | 25.35 | 29.89 | 15.48 | 16.01 | 16.85 | 17.46 | 34.10 | 33.17 | 32.73 | 34.57 | 31.95 | 36.16 | 33.21 | 26.76 | 21.95 | 22.24 | 25.48 | ||||||
| Elevance Health Inc. | 18.25 | 17.06 | 13.59 | 13.21 | 14.05 | 12.71 | 15.88 | 14.85 | 16.06 | 18.05 | 19.55 | 19.80 | 18.14 | 17.03 | 17.46 | 19.20 | 18.75 | 18.07 | 20.46 | ||||||
| Medtronic PLC | 26.93 | 28.35 | 25.37 | 23.73 | 27.24 | 25.62 | 29.00 | 27.97 | 26.49 | 25.70 | 29.96 | 30.94 | 26.88 | 24.40 | 22.61 | 23.38 | 29.39 | 30.66 | 46.71 | ||||||
| UnitedHealth Group Inc. | 22.81 | 25.98 | 27.44 | 22.20 | 17.59 | 10.73 | 16.05 | 29.75 | 35.85 | 36.59 | 30.38 | 20.53 | 22.75 | 22.15 | 22.01 | 22.46 | 26.13 | 27.70 | 27.29 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
EPS
= (Net income attributable to Intuitive Surgical, Inc.Q3 2026
+ Net income attributable to Intuitive Surgical, Inc.Q2 2026
+ Net income attributable to Intuitive Surgical, Inc.Q1 2026
+ Net income attributable to Intuitive Surgical, Inc.Q4 2025)
÷ No. shares of common stock outstanding
= (522,800,000 + 818,100,000 + 821,500,000 + 794,800,000)
÷ 346,643,718 = 8.53
3 Closing price as at the filing date of Intuitive Surgical Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= 428.12 ÷ 8.53 = 50.18
5 Click competitor name to see calculations.
The analysis of valuation metrics reveals a period of substantial earnings growth accompanied by significant volatility in market valuation. While fundamental performance improved consistently over the majority of the observed period, the market valuation multiple underwent a distinct cycle of expansion and subsequent contraction.
- Earnings per Share (EPS) Trajectory
- Earnings per share demonstrated a sustained upward trend, increasing from 4.58 US$ in March 2022 to a peak of 8.88 US$ in June 2026. This consistent growth indicates a strengthening of underlying profitability and operational efficiency over the five-year span, with only a marginal decline observed in the final quarter to 8.53 US$.
- Share Price Movement
- The share price experienced a strong bullish trend through late 2024, rising from 252.34 US$ in March 2022 to a high of 571.88 US$ in December 2024. Following this peak, the price entered a phase of heightened volatility, characterized by a sharp decline to 350.06 US$ in June 2026 before recovering to 428.12 US$ by September 2026.
- Price-to-Earnings (P/E) Ratio Analysis
- The P/E ratio indicates a significant shift in market sentiment. A period of valuation expansion is evident from March 2022 (55.10) through December 2024, where the ratio peaked at 87.82, signaling that price appreciation significantly outpaced earnings growth. This was followed by a period of valuation compression throughout 2025 and early 2026, with the ratio dropping to a period low of 39.40 in June 2026, before settling at 50.18 in September 2026.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 346,643,718 | 353,278,038 | 354,162,842 | 355,130,237 | 354,496,073 | 358,476,506 | 358,418,255 | 356,656,964 | 356,179,445 | 355,354,176 | 354,705,822 | 352,325,863 | 352,071,592 | 351,354,675 | 350,398,068 | 350,389,679 | 353,384,570 | 357,111,192 | 358,956,511 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Income from operations (in thousands) | 592,600) | 971,900) | 855,300) | 864,300) | 759,700) | 743,400) | 578,100) | 734,900) | 577,300) | 567,300) | 469,400) | 450,200) | 465,800) | 463,200) | 387,600) | 372,500) | 398,900) | 397,600) | 408,100) | ||||||
| Operating profit per share2 | 9.47 | 9.77 | 9.10 | 8.29 | 7.94 | 7.35 | 6.86 | 6.59 | 5.80 | 5.50 | 5.21 | 5.01 | 4.80 | 4.62 | 4.44 | 4.50 | 4.68 | 4.76 | 5.05 | ||||||
| Share price1, 3 | 428.12 | 350.06 | 483.62 | 478.88 | 527.03 | 501.95 | 487.93 | 571.88 | 521.15 | 455.01 | 366.34 | 378.22 | 266.91 | 323.56 | 297.41 | 245.27 | 218.49 | 211.85 | 252.34 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | 45.19 | 35.83 | 53.15 | 57.74 | 66.34 | 68.32 | 71.16 | 86.83 | 89.92 | 82.80 | 70.29 | 75.42 | 55.63 | 70.08 | 66.95 | 54.49 | 46.65 | 44.54 | 49.98 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| Abbott Laboratories | 30.10 | 25.27 | 20.65 | 24.21 | 28.05 | 29.77 | 31.90 | 34.28 | 29.37 | 28.44 | 28.99 | 30.54 | 27.48 | 30.47 | 27.70 | 22.18 | 18.35 | 18.63 | 21.33 | ||||||
| Elevance Health Inc. | 19.01 | 17.26 | 12.89 | 11.39 | 11.23 | 9.63 | 12.70 | 12.19 | 13.12 | 14.89 | 15.42 | 15.57 | 14.38 | 13.36 | 13.61 | 15.05 | 15.30 | 14.72 | 17.53 | ||||||
| Medtronic PLC | 20.60 | 21.74 | 19.31 | 18.58 | 20.83 | 20.31 | 22.10 | 19.98 | 19.69 | 18.94 | 19.27 | 21.20 | 19.53 | 17.99 | 19.55 | 20.48 | 25.40 | 27.20 | 38.83 | ||||||
| UnitedHealth Group Inc. | 15.15 | 16.93 | 17.54 | 14.12 | 11.74 | 7.43 | 10.60 | 13.27 | 15.94 | 16.11 | 14.49 | 14.20 | 15.63 | 15.33 | 15.41 | 15.89 | 18.75 | 19.96 | 19.69 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Operating profit per share
= (Income from operationsQ3 2026
+ Income from operationsQ2 2026
+ Income from operationsQ1 2026
+ Income from operationsQ4 2025)
÷ No. shares of common stock outstanding
= (592,600,000 + 971,900,000 + 855,300,000 + 864,300,000)
÷ 346,643,718 = 9.47
3 Closing price as at the filing date of Intuitive Surgical Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 428.12 ÷ 9.47 = 45.19
5 Click competitor name to see calculations.
The analysis of valuation ratios from March 2022 through September 2026 reveals a period of significant valuation expansion followed by a corrective phase, occurring against a backdrop of consistent growth in operational profitability.
- Operating Profit Performance
- Operating profit per share exhibited a resilient upward trajectory over the analyzed period. Following a minor contraction between March 2022 and March 2023, where values moved from 5.05 US$ to 4.44 US$, a sustained growth pattern emerged. This fundamental improvement culminated in a peak of 9.77 US$ by June 2026, indicating a steady increase in the company's operational efficiency and earning power per share.
- Share Price Dynamics
- The share price underwent a strong bullish phase from late 2022 through December 2024, ascending from 245.27 US$ to a period high of 571.88 US$. This growth was followed by a period of instability throughout 2025 and 2026, characterized by a sharp decline to 350.06 US$ in June 2026, before a partial recovery to 428.12 US$ by September 2026.
- Price to Operating Profit (P/OP) Valuation Trends
- The P/OP ratio demonstrates significant volatility and a notable valuation premium that peaked in September 2024 at 89.92. This peak suggests a period where market pricing significantly outpaced the growth of operating profits. A subsequent contraction is observed starting in late 2024, with the ratio declining to 53.15 by December 2025. A sharp correction occurred in June 2026, with the ratio reaching a low of 35.83, reflecting a substantial reset in market valuation relative to operational earnings before recovering to 45.19 in the final quarter analyzed.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 346,643,718 | 353,278,038 | 354,162,842 | 355,130,237 | 354,496,073 | 358,476,506 | 358,418,255 | 356,656,964 | 356,179,445 | 355,354,176 | 354,705,822 | 352,325,863 | 352,071,592 | 351,354,675 | 350,398,068 | 350,389,679 | 353,384,570 | 357,111,192 | 358,956,511 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Revenue (in thousands) | 3,048,700) | 2,892,300) | 2,770,800) | 2,866,200) | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | ||||||
| Sales per share2 | 33.40 | 31.23 | 29.88 | 28.34 | 27.11 | 25.51 | 24.31 | 23.42 | 22.09 | 21.31 | 20.63 | 20.22 | 19.46 | 18.97 | 18.35 | 17.76 | 17.31 | 16.70 | 16.45 | ||||||
| Share price1, 3 | 428.12 | 350.06 | 483.62 | 478.88 | 527.03 | 501.95 | 487.93 | 571.88 | 521.15 | 455.01 | 366.34 | 378.22 | 266.91 | 323.56 | 297.41 | 245.27 | 218.49 | 211.85 | 252.34 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | 12.82 | 11.21 | 16.19 | 16.90 | 19.44 | 19.68 | 20.07 | 24.42 | 23.60 | 21.35 | 17.76 | 18.71 | 13.72 | 17.06 | 16.21 | 13.81 | 12.62 | 12.69 | 15.34 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| Abbott Laboratories | 4.15 | 3.98 | 3.52 | 4.40 | 4.94 | 5.19 | 5.37 | 5.58 | 4.77 | 4.53 | 4.57 | 4.93 | 4.13 | 4.64 | 4.64 | 4.25 | 3.85 | 4.18 | 4.42 | ||||||
| Elevance Health Inc. | 0.47 | 0.43 | 0.36 | 0.38 | 0.40 | 0.36 | 0.52 | 0.51 | 0.60 | 0.71 | 0.72 | 0.70 | 0.66 | 0.66 | 0.68 | 0.74 | 0.77 | 0.75 | 0.89 | ||||||
| Medtronic PLC | 3.50 | 3.89 | 3.46 | 3.30 | 3.50 | 3.33 | 3.50 | 3.18 | 3.44 | 3.30 | 3.44 | 3.72 | 3.55 | 3.42 | 3.79 | 3.72 | 4.54 | 4.54 | 5.74 | ||||||
| UnitedHealth Group Inc. | 0.81 | 0.82 | 0.74 | 0.60 | 0.72 | 0.55 | 0.88 | 1.08 | 1.32 | 1.35 | 1.24 | 1.25 | 1.39 | 1.35 | 1.37 | 1.40 | 1.62 | 1.66 | 1.61 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Sales per share
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ No. shares of common stock outstanding
= (3,048,700,000 + 2,892,300,000 + 2,770,800,000 + 2,866,200,000)
÷ 346,643,718 = 33.40
3 Closing price as at the filing date of Intuitive Surgical Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 428.12 ÷ 33.40 = 12.82
5 Click competitor name to see calculations.
The analysis reveals a steady upward trajectory in sales per share, contrasted with significant volatility in share price and the resulting Price-to-Sales (P/S) ratio. While revenue generation per share grew consistently from 16.45 USD in March 2022 to 33.40 USD by September 2026, the market valuation experienced distinct cycles of expansion and contraction.
- Sales per Share Growth
- A consistent linear increase is observed throughout the analyzed period. Revenue efficiency improved steadily, with sales per share more than doubling over the timeframe, indicating a stable and predictable growth in the underlying business performance.
- Valuation Expansion Phase
- The P/S ratio entered a period of significant expansion starting in 2023 and peaking in December 2024 at 24.42. This peak coincides with the highest recorded share price of 571.88 USD, suggesting that investor sentiment and share price appreciation substantially outpaced actual revenue growth during this window.
- Valuation Compression and Correction
- Following the late 2024 peak, a sustained downward trend in the P/S ratio is evident. The ratio declined through 2025 and reached a notable low of 11.21 in June 2026. This compression indicates a market correction where the share price decreased more rapidly than the underlying sales growth, eventually returning the valuation to levels comparable to those seen in early 2022.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 346,643,718 | 353,278,038 | 354,162,842 | 355,130,237 | 354,496,073 | 358,476,506 | 358,418,255 | 356,656,964 | 356,179,445 | 355,354,176 | 354,705,822 | 352,325,863 | 352,071,592 | 351,354,675 | 350,398,068 | 350,389,679 | 353,384,570 | 357,111,192 | 358,956,511 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Intuitive Surgical, Inc. stockholders’ equity (in thousands) | 15,986,200) | 18,168,400) | 17,474,500) | 17,824,000) | 16,929,700) | 17,845,700) | 17,106,400) | 16,433,700) | 15,583,300) | 14,708,300) | 13,962,600) | 13,307,600) | 12,539,000) | 11,879,100) | 11,217,700) | 11,041,900) | 11,515,400) | 12,023,000) | 12,102,300) | ||||||
| Book value per share (BVPS)2 | 46.12 | 51.43 | 49.34 | 50.19 | 47.76 | 49.78 | 47.73 | 46.08 | 43.75 | 41.39 | 39.36 | 37.77 | 35.61 | 33.81 | 32.01 | 31.51 | 32.59 | 33.67 | 33.72 | ||||||
| Share price1, 3 | 428.12 | 350.06 | 483.62 | 478.88 | 527.03 | 501.95 | 487.93 | 571.88 | 521.15 | 455.01 | 366.34 | 378.22 | 266.91 | 323.56 | 297.41 | 245.27 | 218.49 | 211.85 | 252.34 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | 9.28 | 6.81 | 9.80 | 9.54 | 11.04 | 10.08 | 10.22 | 12.41 | 11.91 | 10.99 | 9.31 | 10.01 | 7.49 | 9.57 | 9.29 | 7.78 | 6.71 | 6.29 | 7.48 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| Abbott Laboratories | 3.92 | 3.63 | 3.06 | 3.74 | 4.25 | 4.42 | 4.66 | 4.91 | 4.94 | 4.69 | 4.75 | 5.12 | 4.40 | 5.02 | 5.21 | 5.06 | 4.85 | 5.21 | 5.56 | ||||||
| Elevance Health Inc. | 2.10 | 1.89 | 1.62 | 1.70 | 1.77 | 1.56 | 2.21 | 2.15 | 2.35 | 2.86 | 3.01 | 3.02 | 2.87 | 2.86 | 2.90 | 3.19 | 3.24 | 3.08 | 3.55 | ||||||
| Medtronic PLC | 2.54 | 2.78 | 2.47 | 2.30 | 2.35 | 2.27 | 2.38 | 2.05 | 2.15 | 2.05 | 2.12 | 2.26 | 2.12 | 2.03 | 2.23 | 2.24 | 2.75 | 2.77 | 3.52 | ||||||
| UnitedHealth Group Inc. | 3.69 | 3.73 | 3.38 | 2.84 | 3.23 | 2.41 | 3.73 | 4.63 | 5.43 | 5.77 | 5.38 | 5.18 | 5.84 | 5.68 | 5.60 | 5.81 | 6.80 | 6.94 | 6.54 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
BVPS = Total Intuitive Surgical, Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= 15,986,200,000 ÷ 346,643,718 = 46.12
3 Closing price as at the filing date of Intuitive Surgical Inc. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 428.12 ÷ 46.12 = 9.28
5 Click competitor name to see calculations.
The valuation metrics from March 2022 through September 2026 exhibit a period of significant expansion in market valuation followed by increased volatility. The relationship between market price and book value reflects a general trend of premium valuation that peaked in late 2024, subsequently undergoing a period of correction and stabilization.
- Share Price Dynamics
- The share price demonstrated substantial growth, rising from 252.34 in March 2022 to a peak of 571.88 in December 2024. Following this peak, the price entered a volatile phase, characterized by a significant decline to 350.06 in June 2026 before recovering to 428.12 by September 2026. This suggests a period of aggressive market appreciation followed by a price correction.
- Book Value Per Share (BVPS) Evolution
- BVPS maintained a generally positive trajectory, increasing from 33.72 in March 2022 to a high of 51.43 in June 2026. While the growth was more stable than the share price, minor fluctuations occurred, including a slight decrease to 31.51 in December 2022 and a late-period dip to 46.12 in September 2026. The overall trend indicates a steady accumulation of net assets over the analyzed period.
- Price to Book Value (P/BV) Ratio Analysis
- The P/BV ratio fluctuated between a minimum of 6.29 in June 2022 and a maximum of 12.41 in December 2024. A notable expansion in the ratio is observed between 2023 and late 2024, indicating that the market was attributing an increasing premium to the company's assets. A sharp contraction occurred in June 2026, where the ratio fell to 6.81, reflecting a realignment of the market price closer to the underlying book value. The period closed with a rebound to 9.28, suggesting a return to a higher valuation multiple.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?